Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Head and Neck Carcinoma|Adenoid Cystic Carcinoma|Cervical Cancer|Breast Cancer|Lung Cancer|Non-Small Cell Lung Cancer|Mesothelioma|Thymic Carcinoma|Bladder Cancer|Ovarian Cancer|Pancreatic Cancer|Sarcoma|Any Solid Tumors Progressed After a Prior Immunotherapy
Interventions: DRUG: VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)
Sponsor: VM Oncology, LLC